Also trades as: IPA.V (TSXV)
IPA NASDAQ
ImmunoPrecise Antibodies Ltd.
1W: -2.8%
1M: +8.9%
3M: -33.1%
1Y: +258.3%
3Y: -66.4%
5Y: -75.8%
$1.62
Last traded 2025-11-17 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$25M
+0.0% ▲
5Y CAGR: +11.8%
Gross Profit
$14M
+12.4% ▲
5Y CAGR: +11.0%
Operating Income
-$12M
+11.4% ▲
Net Income
-$30M
-11.2% ▼
EPS (Diluted)
$-0.91
+14.2% ▲
EBITDA
-$29M
-25.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $18M | $19M | $21M | $25M | $25M |
| YoY Growth | +27.4% | +8.1% | +6.7% | +18.6% | +0.0% |
| Cost of Revenue | $6M | $8M | $9M | $12M | $11M |
| Gross Profit | $12M | $11M | $12M | $12M | $14M |
| Gross Margin | 64.4% | 56.7% | 56.0% | 49.2% | 55.3% |
| R&D Expenses | $2M | $8M | $14M | $4M | $5M |
| SG&A Expenses | $13M | $18M | $19M | $19M | $19M |
| Operating Expenses | $16M | $26M | $37M | $26M | $26M |
| Operating Income | -$4M | -$15M | -$26M | -$14M | -$12M |
| Operating Margin | -23.3% | -79.8% | -123.9% | -56.1% | -49.7% |
| Interest Expense | $863K | $85K | $30K | $19K | $293K |
| Income Before Tax | -$6M | -$16M | -$28M | -$29M | -$34M |
| Tax Expense | $1M | $861K | -$1M | -$2M | -$4M |
| Net Income | -$7M | -$17M | -$27M | -$27M | -$30M |
| Net Margin | -41.0% | -86.3% | -128.5% | -110.8% | -123.3% |
| EPS (Diluted) | $-0.45 | $-0.85 | $-1.07 | $-1.06 | $-0.91 |
| EBITDA | -$1M | -$12M | -$21M | -$23M | -$29M |
| Shares Outstanding | 16M | 20M | 25M | 26M | 33M |